FENNEC PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On November 29, 2021, Fennec Pharmaceuticals Inc. issued a news release announcing that it expects the U.S. Food and Drug Administration will not accept the company's New Drug Application for PEDMARK™ (a unique formulation of sodium thiosulfate). PEDMARK is an investigational drug for reducing the risk of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

 (d) Exhibits.




Exhibit No.      Description

  Exhibit 99.1     Press Release dated November 29, 2021
Exhibit 104      Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses